What is Janux Therapeutics's G&A?

Janux Therapeutics (JANX) reported G&A of $11.13M in Q1 2026.

How has Janux Therapeutics's G&A changed year-over-year?

Janux Therapeutics's G&A increased by 13.1% year-over-year, from $9.84M to $11.13M.

What is the long-term trend for Janux Therapeutics's G&A?

Over 4 years (2021 to 2025), Janux Therapeutics's G&A has grown at a 41.8% compound annual growth rate (CAGR), from $10.33M to $41.77M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Janux Therapeutics JANX G&A

G&A at other companies

XencorXNCR

$17.71M+2.1%

Vor BiopharmaVOR

$17.57M+167%

Cullinan Therapeutics, Inc.CGEM

$11.57M-14.5%

Nektar TherapeuticsNKTR

$13.44M-44.8%

Arcus BiosciencesRCUS

$29M+3.6%

ImmunomeIMNM

$12.95M+21.1%

Other financials

Income statement

See full

Revenue$3.7M—

Operating income-$34.2M+2.0%

Net income-$24.4M-3.6%

EPS (diluted)-$0.39-2.6%

Balance sheet

See full

Cash & equivalents$51.8M-29.7%

Total debt$21.6M-4.6%

Total equity$941.5M-7.0%

Total assets$1.0B-2.1%

Cash flow

See full

Operating cash flow-$12.3M+27.5%

CapEx$273.0K-26.4%

Free cash flow-$12.6M+27.5%

Valuation

See full

Market cap$892.81M-36.1%

Enterprise value$862.55M-35.9%

P/S65×-84.6×

Profitability

See full

Operating margin-1,143.1%-65.1pp

Net margin-833.6%+0.9pp

FCF margin-571.6%+98.3pp

Returns & leverage

See full

Return on equity-11.7%+4.1pp

Debt / equity0×0.0×

Current ratio17×-41.5×

Where this comes from

Reported directly by Janux Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Janux Therapeutics's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Janux Therapeutics's G&A?: Janux Therapeutics (JANX) reported G&A of $11.13M in Q1 2026.
How has Janux Therapeutics's G&A changed year-over-year?: Janux Therapeutics's G&A increased by 13.1% year-over-year, from $9.84M to $11.13M.
What is the long-term trend for Janux Therapeutics's G&A?: Over 4 years (2021 to 2025), Janux Therapeutics's G&A has grown at a 41.8% compound annual growth rate (CAGR), from $10.33M to $41.77M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.